Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin.
In order to utilize macromolecules for drug targeting and delivery, a strategy to tether organometallic ruthenium-arene drugs to carrier protein molecules was developed. The approach involves the design of a drug fragment capable of conjugating to linker molecules on a modified carrier protein via hydrazone bond formation. The proof-of-concept using recombinant human serum albumin is described.
Ang
Wee Han
WH
Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Daldini
Elisa
E
Juillerat-Jeanneret
Lucienne
L
Dyson
Paul J
PJ
D000970:Antineoplastic Agents / Q000737:chemistry*; D006801:Humans; D009942:Organometallic Compounds / Q000737:chemistry*; D011994:Recombinant Proteins / Q000737:chemistry; D012428:Ruthenium / Q000737:chemistry*; D012709:Serum Albumin / Q000737:chemistry*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D011994:Recombinant Proteins; D012709:Serum Albumin; D012428:Ruthenium